Most dietary supplements today are sold not as one-time purchases but as recurring subscriptions. Subscription-first companies draw 60% to 80% of sales from recurring orders, and even brands that also sell in retail stores see 30% to 60% [1]. Where checkout defaults to a recurring plan, 40% to 70% of customers stick with it [2]. Modern nutrition's business model rests on one biological assumption: to keep enjoying the benefits, you need to keep taking the product.
Yet nutraceutical study design rarely tests that assumption. A standard randomized controlled trial (RCT) follows a pre-post model: participants take a supplement for a defined period, and biomarkers are measured before and after. This shows what happens when someone starts. What it routinely ignores is the "washout" phase: what happens when they stop. By failing to gather that data, brands miss their most compelling tool for retention.
Historical precedent shows why this matters. Long before subscription websites existed, Eric Hultman's classic 1996 study found that a 6-day creatine loading routine raised muscle creatine levels by roughly 19% [3]. As soon as participants stopped, muscle creatine fell back to baseline within 30 days. Nutrition brands now use this exact timeline to explain why daily use matters.
More recently, a 2026 study found a probiotic improved stress and anxiety scores over six weeks of use, but those benefits largely disappeared four to six weeks after participants stopped [4]. The claim: probiotic benefits may be temporary, and long-term use could be essential to maintain them.
A simple washout phase is valuable, but nutrition trials rarely use the ultimate framework for testing long-term benefit: the Enriched Enrollment Randomized Withdrawal (EERW) design [5]. Rather than tracking everyone after they stop, an EERW trial begins with an open-label phase in which every participant receives the active supplement, filtering out non-responders and those with side effects. The remaining verified responders then split double-blind: half continue the active supplement, half switch to an identical-looking placebo. We then measure how quickly biomarkers between the two groups begin to diverge.
This structure rules out two issues a basic follow-up cannot: regression to the mean, and the psychological expectation effect, where a participant feels worse simply because they know their supplement was taken away. This withdrawal design is standard for testing chronic pain and brain health medications precisely because it proves a treatment's ongoing presence is what keeps the patient healthy. Bringing this rigor to a nutraceutical trial gives a brand a new level of proof to validate its subscription model.

